EU researchers develop simple blood test to detect Alzheimer's decades before symptoms

For decades, Alzheimer's disease has been a diagnosis that arrives too late. By the time memory loss becomes undeniable, the disease has already carved deep channels through the brain. Doctors have tools to confirm what patients already suspect—brain scans, spinal taps that draw fluid from around the spine—but these are expensive, invasive, and they tell you what you already know. A team of European researchers is trying to change that equation entirely, developing a blood test so simple it could sit in a family doctor's office, detecting the disease not when it announces itself but years or decades before the first forgotten name.

The project, called 2D-BioPAD, launched in October 2023 under the direction of Dr. Aristeidis Bakandritsos at the Czech Advanced Technology and Research Institute. The vision is straightforward: take a few milliliters of blood, run it through a device no larger than a glucose meter, and identify up to five proteins linked to Alzheimer's—biomarkers that signal the disease is already at work in the brain. The whole process would take about 30 minutes. The cost would be a fraction of what laboratories charge today, where testing a single biomarker can run €40 or more, and the equipment itself costs hundreds of thousands of euros.

What makes this possible is graphene, a material so thin it is essentially a single atom of carbon, yet stronger than steel and an exceptional conductor of electricity. When Alzheimer's proteins bind to the graphene surface, they alter how electricity flows through it—a change so subtle that conventional tests would miss it, but one that graphene can detect with extraordinary sensitivity. The device works somewhat like the rapid COVID tests millions used during the pandemic, but with far greater analytical power, measuring multiple markers simultaneously rather than a single yes-or-no result.

Timing matters enormously here. Until 2025, Alzheimer's treatment was largely about managing symptoms—slowing the inevitable decline. That year, the European Union approved the first two disease-modifying drugs, medications that actually target amyloid-beta, the protein fragments that accumulate between brain cells and disrupt communication. These drugs work best when started early, when the disease is still in its earliest stages, before neurons have been extensively damaged. A test that could identify people at risk decades before symptoms appear would fundamentally change what doctors could offer them. "Early detection will only be realistic for people when it's inexpensive for the health service, and painless and simple for the patient, which it isn't today," Bakandritsos said.

The numbers underscore the urgency. Seven million people in Europe currently live with Alzheimer's, the most common form of dementia. That figure is expected to double by 2030. The disease is a ticking clock for health systems already stretched thin, and for families watching a parent or grandparent slowly disappear. Clinical trials are now running in Finland, Greece, and Germany, testing not just whether the device works, but whether it is safe, whether people want to know their risk, and how it might fit into routine primary care. By the end of 2026, researchers will have their first real answer about how the technology performs against existing laboratory equipment.

Vincent Bouchiat, CEO of Grapheal SAS, one of the project partners, acknowledges the ethical weight of telling someone they may develop dementia decades hence. But he also points to what has changed: "There are good reasons for knowing you may go on to develop dementia. New Alzheimer's medications show promise in delaying the progression of the disease, which is obviously a huge step forward." Jean Georges, executive director of Alzheimer Europe, echoes this but with a note of caution. "No test can predict exactly who will develop dementia or how it will progress," he said. What it can do is shift the conversation from treatment alone to prevention, from waiting for symptoms to emerge to catching the disease while intervention still has time to work.

The 2D-BioPAD project brings together 11 partners across 8 European countries, combining expertise in nanotechnology, clinical research, and artificial intelligence. Machine learning helps design the molecular probes that detect Alzheimer's proteins, optimizing them through rapid simulations. If the trials succeed, if regulators approve, if funding materializes for the next phase, the researchers believe the test could be in routine use within five years. A small blood sample, a compact device, a tablet or smartphone to display results—the apparatus of early detection made ordinary, made accessible, made part of the everyday work of keeping people well.